Product Description
Mechanisms of Action: CD80 Binder,CD86 Binder
Novel Mechanism: Yes
Modality: Antibody
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: XTL
Company Location: NEW YORK NY 10016
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Hepatitis B
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
2004-000501-21 | P2 |
Completed |
Hepatitis B |
2005-08-30 |